Improved Survival in Stage IV Breast Cancer with DCT

The study aimed to assess the impact of immunotherapy in 368 patients with stage IV breast cancer. The patients were divided into two groups: one receiving a combination of DC-CIK immunotherapy after low-dose chemotherapy, and the other receiving chemotherapy alone (the control group).

Combining DCT with Chemotherapy in Metastatic Prostate Cancer: Phase I/II Clinical Trial

In this study, researchers present the results of a Phase I/II clinical trial conducted on patients with metastatic castration-resistant prostate cancer (mCRPC). The trial focused on a novel approach using docetaxel in combination with autologous mature dendritic cells (DCs) that were specially treated with killed LNCaP prostate cancer cells (DCVAC/PCa).

Triple Negative Breast Cancer: pDC vs. cDC | STUDY

The groundbreaking findings showed that high levels of pDC were significantly associated with improved survival in triple negative breast cancer (TNBC), whereas cDC did not show the same correlation.

Unraveling Dendritic Cells in Glioblastoma Immunotherapy

Glioblastoma (GBM), a devastating primary brain cancer, remains a formidable challenge with a median survival of less than 15 months despite current standard treatments of surgery, radiation, and chemotherapy.

STUDY: Dendritic Cell Vaccine Therapy for Colorectal Cancer

In the pursuit of disrupting tumor growth, a groundbreaking approach emerges through dendritic cell (DC) vaccines that target tumor-derived blood vessels, unleashing potent immune responses to combat cancer.

Concise Review: Prostate Cancer Diversity: Unveiling Complexity

Prostate cancer (PCa) is a complex disease with diverse cancer cell types, each contributing to its heterogeneity.